Similar articles for PMID: 15950494

Year	Number of Results
1988	1
2001	1
2002	3
2003	2
2004	6
2005	21
2006	7
2007	6
2008	9
2009	9
2010	13
2011	10
2012	5
2013	8
2014	5
2015	7
2016	14
2017	11
2018	4
2019	3
2020	7
2021	3
2022	1
2023	1
2024	0

1

HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk.

Wible BA, Hawryluk P, Ficker E, Kuryshev YA, Kirsch G, Brown AM. Wible BA, et al. J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):136-45. doi: 10.1016/j.vascn.2005.03.008. J Pharmacol Toxicol Methods. 2005. PMID: 15950494

2

Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.

Guo L, Guthrie H. Guo L, et al. J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):123-35. doi: 10.1016/j.vascn.2005.04.002. J Pharmacol Toxicol Methods. 2005. PMID: 15936217

3

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.

Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. Redfern WS, et al. Cardiovasc Res. 2003 Apr 1;58(1):32-45. doi: 10.1016/s0008-6363(02)00846-5. Cardiovasc Res. 2003. PMID: 12667944 Review.

4

Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.

Deacon M, Singleton D, Szalkai N, Pasieczny R, Peacock C, Price D, Boyd J, Boyd H, Steidl-Nichols JV, Williams C. Deacon M, et al. J Pharmacol Toxicol Methods. 2007 May-Jun;55(3):238-47. doi: 10.1016/j.vascn.2006.09.003. Epub 2006 Oct 18. J Pharmacol Toxicol Methods. 2007. PMID: 17141530

5

Nonclinical proarrhythmia models: predicting Torsades de Pointes.

Lawrence CL, Pollard CE, Hammond TG, Valentin JP. Lawrence CL, et al. J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):46-59. doi: 10.1016/j.vascn.2005.04.011. J Pharmacol Toxicol Methods. 2005. PMID: 15975832 Review.

6

Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies.

Shah RR. Shah RR. Novartis Found Symp. 2005;266:251-80; discussion 280-5. Novartis Found Symp. 2005. PMID: 16050273 Review.

7

Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature.

Yao JA, Du X, Lu D, Baker RL, Daharsh E, Atterson P. Yao JA, et al. J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):146-53. doi: 10.1016/j.vascn.2005.04.008. J Pharmacol Toxicol Methods. 2005. PMID: 15936218

8

Acquired QT interval prolongation and HERG: implications for drug discovery and development.

Finlayson K, Witchel HJ, McCulloch J, Sharkey J. Finlayson K, et al. Eur J Pharmacol. 2004 Oct 1;500(1-3):129-42. doi: 10.1016/j.ejphar.2004.07.019. Eur J Pharmacol. 2004. PMID: 15464027 Review.

9

Blockade of HERG channels by HIV protease inhibitors.

Anson BD, Weaver JG, Ackerman MJ, Akinsete O, Henry K, January CT, Badley AD. Anson BD, et al. Lancet. 2005 Feb 19-25;365(9460):682-6. doi: 10.1016/S0140-6736(05)17950-1. Lancet. 2005. PMID: 15721475

10

Predicting drug-hERG channel interactions that cause acquired long QT syndrome.

Sanguinetti MC, Mitcheson JS. Sanguinetti MC, et al. Trends Pharmacol Sci. 2005 Mar;26(3):119-24. doi: 10.1016/j.tips.2005.01.003. Trends Pharmacol Sci. 2005. PMID: 15749156 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

133 results

Results by year